Zolmitriptan Od Medication Summary
No separate FDA Medication Guide was found for this label. This summary is based on FDA/DailyMed prescribing information.
What is this medication?
Zolmitriptan OD is described in FDA/DailyMed prescribing information. No separate FDA Medication Guide was found for this label. This summary is based on FDA/DailyMed prescribing information.
What is this medication used for?
Zolmitriptan orally disintegrating tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use Only use zolmitriptan orally disintegrating tablets are if a clear diagnosis of migraine has been established. If a patient has no response to zolmitriptan orally disintegrating tablets are treatment for the first migraine attack, reconsider the diagnosis of migraine before zolmitriptan orally disintegrating tablets are administered to treat any subsequent attacks.Zolmitriptan orally disintegrating tablets are not indicated for the prevention of migraine attacks.Safety and effectiveness of zolmitriptan orally disintegrating tablets have not been.
What should I know before taking it?
Zolmitriptan orally disintegrating tablets are contraindicated in patients with: Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), other significant underlying cardiovascular disease, or coronary artery vasospasm including Prinzmetal’s angina [see Warnings and Precautions (5.1)] . Wolff-Parkinson-White Syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions (5.2)]. History of stroke, transient ischemic attack (TIA), or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see Warnings and Precautions (5.4)].
What important warnings are listed?
5 WARNINGS AND PRECAUTIONS Myocardial Ischemia/Infarction, and Prinzmetal Angina: Perform cardiac evaluation in patients with multiple cardiovascular risk factors ( 5.1 ) Arrhythmias: Discontinue zolmitriptan if occurs ( 5.2 ) Chest/Throat/Neck/Jaw Pain, Tightness, and Pressure : Generally not associated with myocardial ischemia; evaluate for CAD in patients at high risk ( 5.3 ) Cerebral Hemorrhage, Subarachnoid Hemorrhage, and Stroke: Discontinue zolmitriptan if occurs ( 5.4 ) Gastrointestinal Ischemic Reactions and Peripheral Vasospastic Reactions: Discontinue zolmitriptan if occurs ( 5.5 ) Medication Overuse Headache : Detoxification may be necessary ( 5.6 ) Serotonin Syndrome:.
How is this medication usually taken?
2.5 mg Zolmitriptan Orally Disintegrating Tablets, USP: White, round, flat faced, beveled edged tablets, debossed with ‘C’ on one side and ‘J’ on the other side. 5 mg Zolmitriptan Orally Disintegrating Tablets, USP: White, round, flat faced, beveled edged tablets, debossed with ‘C’ on one side and ‘K’ on the other side.
What side effects are listed?
The following adverse reactions are described elsewhere in other sections of the prescribing information: Myocardial Ischemia, Myocardial Infarction, and Prinzmetal Angina [see Warnings and Precautions (5.1)]. Arrhythmias [ see Warnings and Precautions (5.2) ]. Chest and or Throat, Neck and Jaw Pain/Tightness/Pressure [see Warnings and Precautions (5.3)]. Cerebrovascular Events [see Warnings and Precautions (5.4)]. Other Vasospasm Reactions [see Warnings and Precautions (5.5) ]. Medication Overuse Headache [see Warnings and Precautions (5.6) ]. Serotonin Syndrome [see Warnings and Precautions (5.7) ]. Increase in Blood Pressure [see Warnings and Precautions (5.8) ].
What interactions are listed?
7 DRUG INTERACTIONS 7.1 Ergot-containing Drugs Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and zolmitriptan within 24 hours of each other is contraindicated [see Contraindications (4)] . 7.2 MAO-A Inhibitors MAO-A inhibitors increase the systemic exposure of zolmitriptan and its active N-desmethyl metabolite. Therefore, the use of zolmitriptan in patients receiving MAO-A inhibitors is contraindicated [see Contraindications (4) and Clinical Pharmacology (12.3) ]. 7.3 5-HT1B/1D agonists Concomitant use of other 5-HT.
Where can I find the official prescribing information?
Review the full prescribing information on DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f0040a6-b1d6-3d73-e063-6294a90af23c
⚠️ Disclaimer
This summary is for educational purposes only and is not medical advice. Always consult your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine. Read full medical disclaimer.